This is a ready-to-use resin or membrane lifetime (column reuse) validation protocol. Replace every <<FILL: ...>> placeholder with your own specifics, set your document numbers and dates, and route it through your normal document control, review, and approval before execution. A worked filled specimen follows. Verify each cited regulation against the current source before you rely on it.
Approval page (execute only after all signatures)
| Field | Entry |
|---|---|
| Protocol title | Resin/Membrane Lifetime Study for <<FILL: STEP NAME, e.g. Protein A capture column>> |
| Protocol number | <<FILL: PROT-ID, e.g. VAL-RL-004>> |
| Version | <<FILL: version>> |
| Effective date | <<FILL: date>> |
| Supersedes | <<FILL: prior version or "New">> |
| Target cycle claim | <<FILL: e.g. up to 150 cycles>> |
| Role | Name | Signature | Date |
|---|---|---|---|
| Author (Process development / Validation) | <<FILL>> | ||
| Manufacturing / MSAT | <<FILL>> | ||
| QC (analytical) | <<FILL>> | ||
| Quality Assurance (approver) | <<FILL>> |
1. Objective
To demonstrate that <<FILL: RESIN/MEMBRANE NAME>> used at <<FILL: STEP NAME>> continues to deliver acceptable yield, product quality, and impurity clearance through <<FILL: target cycle count>> cycles, and to establish the validated maximum reuse limit.
2. Scope
In scope: small-scale (bench) cycling study using a qualified scale-down model of <<FILL: STEP NAME>>, plus the concurrent at-scale confirmation plan (section 9). Out of scope: viral clearance at end-of-life resin, which is addressed by a separate protocol that consumes the aged material this study generates; see Protocol: Viral Clearance (Spiking) Study.
3. Scale-down model qualification (prerequisite)
| Attribute | Manufacturing scale | Scale-down model | Equivalent? |
|---|---|---|---|
| Bed height / membrane area | <<FILL>> | <<FILL>> | <<FILL>> |
| Linear velocity / flux | <<FILL>> | <<FILL>> | <<FILL>> |
| Load ratio | <<FILL>> | <<FILL>> | <<FILL>> |
| Buffers, pH, conductivity | <<FILL>> | <<FILL>> | <<FILL>> |
Scale-down model qualification report reference: <<FILL>>.
4. Cycle sequence (must match manufacturing exactly)
| Step | Condition |
|---|---|
| Equilibration | <<FILL>> |
| Load | <<FILL>> |
| Wash(es) | <<FILL>> |
| Elution | <<FILL>> |
| Regeneration | <<FILL>> |
| Sanitization | <<FILL: chemistry, e.g. NaOH concentration, contact time>> |
| Storage | <<FILL: storage solution, temperature, max hold>> |
Omitting the actual sanitization/regeneration chemistry from the cycle sequence understates degradation and invalidates the claim; confirm every cycle in this study runs the real chemistry.
5. Monitored attributes and sampling points
| Attribute | Method | Sampled at cycles |
|---|---|---|
| Step yield / recovery | <<FILL: e.g. A280 mass balance>> | <<FILL: every cycle or defined subset>> |
| Aggregates (HMW) | <<FILL: SEC>> | <<FILL>> |
| Charge variants | <<FILL: IEX>> | <<FILL>> |
| Host cell protein | <<FILL: ELISA>> | <<FILL>> |
| Leached ligand (capture steps) | <<FILL: ligand ELISA>> | <<FILL>> |
| Host cell DNA | <<FILL: qPCR>> | <<FILL>> |
| Chromatographic performance (HETP, asymmetry) | <<FILL: packing/qualification test>> | <<FILL>> |
| Back-pressure | <<FILL: in-line pressure log>> | Every cycle |
| Carryover | <<FILL: blank run>> | <<FILL>> |
| Bioburden / endotoxin | <<FILL>> | <<FILL>> |
Sample more frequently near the beginning, the middle, and the end-of-life region so a drift is caught with enough resolution to defend the limit.
6. Responsibilities
| Role | Responsibility |
|---|---|
| Process development / MSAT | Designs and executes the bench cycling study, sets monitored attributes |
| Manufacturing | Executes concurrent at-scale monitoring, maintains the column-life log |
| QC | Runs the analytical assays at each sampled cycle |
| Validation lead | Owns the protocol/report and the resulting validated limit |
| QA | Approves limits, confirms the cycle counter and discard rule are enforced |
7. Test cases (attribute trend, one row family per sampled cycle)
| TC ID | Cycle number | Attribute | Limit | Result | Pass/Fail |
|---|---|---|---|---|---|
| TC-01 | 1 | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-02 | <<FILL: mid-point>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-03 | <<FILL: target count>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
| TC-04 | <<FILL: margin, beyond target>> | <<FILL>> | <<FILL>> | <<FILL>> | <<FILL>> |
8. Acceptance criteria
- Every monitored attribute stays within its predefined limit through the target cycle count.
- Trends are understood (a slow, explainable drift is acceptable; an erratic or unexplained shift is not).
- Carryover is controlled (blank run shows no meaningful product/impurity signal).
- The margin cycles (beyond the target count) still pass, so the validated limit is not set at a cliff edge.
- End-of-life material from this study is used (or its condition is used to justify a separate challenge) in the viral clearance study.
9. Concurrent at-scale confirmation plan
State how the small-scale claim will be confirmed during commercial production: <<FILL: e.g. monitor the first N production columns cycle-by-cycle against the same attribute panel; report deviations from the bench trend to Validation and QA>>. If launching on an interim claim supported by small-scale data alone, state the justification and the commitment date to close the concurrent confirmation: <<FILL>>.
10. Deviation handling
Any deviation (an attribute trending outside the expected range before the target cycle, a missed sample point, a process excursion during cycling) is raised through <<FILL: SOP-ID for deviations>> and its impact on the claimed limit is assessed before the study is considered complete.
11. Summary and conclusion (completed at report stage)
Reference the lifetime study report <<FILL: report number>>, which states the validated maximum cycle count, the trend data, all deviations and their disposition, and the concurrent confirmation status.
12. References
FDA Guidance for Industry, Process Validation: General Principles and Practices (January 2011). EMA Guideline on process validation for the manufacture of biotechnology-derived active substances (2016). EudraLex Volume 4, Annex 2 and Annex 15. ICH Q5E, Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process.
Confirm the current version and clause numbers of each reference before issue.
13. Attachments
Scale-down model qualification report; raw analytical data for each sampled cycle; column packing/HETP qualification records; sanitization/regeneration chemistry specification.
14. Revision history
| Version | Date | Author | Summary of change |
|---|---|---|---|
<<FILL: 1.0>> | <<FILL>> | <<FILL>> | Initial issue. |
Filled specimen (excerpt)
Illustrative Protein A capture column, target claim 150 cycles. Numbers are illustrative.
| Cycle | Yield (%) | HCP (ppm) | Leached ligand (ppm) | Aggregate (% HMW) | Back-pressure (bar) |
|---|---|---|---|---|---|
| 1 | 96 | 410 | 8 | 0.9 | 1.8 |
| 100 | 95 | 460 | 11 | 1.1 | 2.1 |
| 150 (target) | 94 | 520 | 14 | 1.2 | 2.3 |
| 175 (margin) | 93 | 610 | 19 | 1.4 | 2.7 |
| Limit | greater than or equal to 90 | less than or equal to 1000 | less than or equal to 30 | less than or equal to 2.0 | less than or equal to 3.5 |
Conclusion (illustrative): every attribute at cycle 150 is comfortably within limit; the margin cycles (175) show the trend beginning to move but still passing. Validated limit: 150 cycles, enforced by a per-column cycle counter tied to the batch record.
Common inspection findings this protocol prevents
- No column-life tracking, or a counter that exists on paper but is not enforced per individual column.
- Lifetime claim supported by small-scale data only, with no concurrent at-scale confirmation ever closed.
- Sanitization/regeneration chemistry left out of the bench cycles, understating real degradation.
- Viral clearance run only on fresh resin, leaving the safety margin unproven at end-of-life.
- Resin lot expiry (a storage control) confused with column cycle life (an in-use control); both are required.
How to adapt this protocol
- Set your protocol number, target cycle claim, and step name in the approval page.
- Confirm scale-down model qualification is complete and attached before cycling begins.
- Build the cycle sequence to match manufacturing exactly, including the real sanitization chemistry.
- Set your monitored attribute panel and sampling density from your own risk assessment.
- Define the concurrent at-scale confirmation plan before commercial launch, not after.
- Confirm every regulation in section 12 against the current published version before issue.